Jay Bradner, M.D., has revealed that Novartis has scrapped one-fifth of its drug programs. The cull is designed to limit Novartis’ pipeline to potentially transformative therapies that fit with the ...
Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development of the DP2 antagonist in asthma. The setback means Amgen, AstraZeneca ...
Novartis Pharmaceuticals Corporation 1 (Novartis) recently entered into a civil settlement agreement with the Department of Justice (DOJ) to resolve allegations that the company paid health care ...
EAST HANOVER, N.J., Oct. 8, 2019 /PRNewswire/ -- Novartis is inviting patient advocacy organizations to submit proposals for programs that offer to expand and improve understanding of biomarker ...
Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare inequities at Historically Black Medical School ...
Novartis Pharmaceuticals Corp. agreed earlier this month to pay $678 million to settle an SDNY False Claims Act case. The SDNY alleged that Novartis violated the False Claims Act and the Anti-Kickback ...
Milestone marks the third major acquisition for an IFM Therapeutics subsidiary in the past seven years The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, ...
EAST HANOVER, N.J., July 12, 2023 /PRNewswire/ -- Novartis and the Novartis US Foundation proudly announce the significant expansion of Beacon of Hope, our 10-year commitment to co-create programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results